Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

Open access
Hamaguchi, T, Kato, K, Yasui, H, Morizane, C, Ikeda, M, Ueno, H, Muro, K, Yamada, Y, Okusaka, T, Shirao, K, Shimada, Y, Nakahama, H, Matsumura, Y · 2007 · British Journal of Cancer

Abstract

This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting dose was 10 mg m(-2), and the dose was escalated according to the accelerated titration method. Nineteen patients were recruited. The tumour types treated included pancreatic (n=11), bile duct (n=5), gastric (n=2), and colonic (n=1) cancers. Neutropenia was the most common haematological toxicity. A grade 3 fever developed in one patient given 180 mg m(-2). No other grades 3 or 4 nonhaematological toxicities, including neuropathy, was observed during the entire study period. DLTs occurred in two patients given 180 mg m(-2) (grade 4 neutropenia lasting for more than 5 days). Thus, this dose was designated as the MTD. Grade 2 hypersensitivity reactions developed in only one patient given 180 mg m(-2). A partial response was observed in one patient with pancreatic cancer. The maximum concentration (C(max)) and area under the concentration (AUC) of NK105 were dose dependent. The plasma AUC of NK105 at 150 mg m(-2) was approximately 15-fold higher than that of the conventional PTX formulation. NK105 was well tolerated, and the RD for the phase II study was determined to be 150 mg m(-2) every 3 weeks. The results of this phase I study warrant further clinical evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6603855

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic structure of NK105. A polymeric micelle carrier of NK105 consists of a block copolymer of PEG (molecular weight of about 12 000) and modified polyaspartate. PEG is believed to be the outer shell of the micelle. PEG is believed to form the outer shell of the micelle. NK105 has a highly hydrophobic inner core, and therefore can entrap a sufficient amount of PTX.
Figure 1 Schematic structure of NK105. A polymeric micelle carrier of NK105 consists of a block copolymer of PEG (molecular weight of about 12 000) and modified polyaspartate. PEG is believed to be the outer shell of the micelle. PEG is believed to form the outer shell of the micelle. NK105 has a highly hydrophobic inner core, and therefore can entrap a sufficient amount of PTX.CC BY · PubMed Central
Figure 2 (A) Individual plasma concentrations of PTX in seven patients following 1-h intravenous infusion of NK105 at a dose of 150 mg m−2. (B) Relationships between dose and Cmax, and (C) between dose and AUC0−inf. of PTX in patients following 1-h intravenous infusion of NK105. Regression analysis for dose vs Cmax was applied using all points except one patient at 80 mg m−2 whose medication time became 11 min longer and one patient at 180 mg m−2 who had medication discontinuation and steroid medication. (Plots were shown as open circle). Regression analysis for dose vs AUC0−inf. was applied using all points except one patient who had medication discontinuation and steroid medication. (Plot was shown as open circle.) Relationships between dose and Cmax, and AUC0−inf. in patients following conventional PTX administration were plotted (closed square, see Tamura et al, 1995).
Figure 2 (A) Individual plasma concentrations of PTX in seven patients following 1-h intravenous infusion of NK105 at a dose of 150 mg m−2. (B) Relationships between dose and Cmax, and (C) between dose and AUC0−inf. of PTX in patients following 1-h intravenous infusion of NK105. Regression analysis for dose vs Cmax was applied using all points except one patient at 80 mg m−2 whose medication time became 11 min longer and one patient at 180 mg m−2 who had medication discontinuation and steroid medication. (Plots were shown as open circle). Regression analysis for dose vs AUC0−inf. was applied using all points except one patient who had medication discontinuation and steroid medication. (Plot was shown as open circle.) Relationships between dose and Cmax, and AUC0−inf. in patients following conventional PTX administration were plotted (closed square, see Tamura et al, 1995).CC BY · PubMed Central
Figure 3 Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the baseline scan. The antitumour response was maintained for nearly 1 year. (B) A 64-year-old male with stomach cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (left panel) showing a peritoneal metastasis and liver metastasis. About 40% reduction (right panel) was observed in peritoneal metastasis, but not in the liver metastasis after fifth course.
Figure 3 Serial CT scans. (A) A 60-year-old male with pancreatic cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (upper panels) showing multiple metastasis in the liver. Partial response, characterized by a more than 90% decrease in the size of the liver metastasis (lower panels) compared with the baseline scan. The antitumour response was maintained for nearly 1 year. (B) A 64-year-old male with stomach cancer who was treated with NK105 at a dose level of 150 mg m−2. Baseline scan (left panel) showing a peritoneal metastasis and liver metastasis. About 40% reduction (right panel) was observed in peritoneal metastasis, but not in the liver metastasis after fifth course.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Deisai N, Trieu V, Yao R (2003) Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol, role of a novel albumin transporter mechanism. 26th Annual San Antonio Breast Cancer Symposium San Antonio, TX

Cited by

See all 312

Metadata

Authors
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., & Matsumura, Y.
Affiliations
  • National Cancer Center Hospital (JP)
  • National Cancer Center Hospital East (JP)
Corresponding author
Hamaguchi, T
Venue
British Journal of Cancer
Published
2007-06-26
Volume
97
Issue
2
Pages
170-176
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W1990869510
Cited by
290
References
24
Citations by year
2026: 8 · 2025: 8 · 2024: 10 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 16 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 18 · 2015: 23 · 2014: 29 · 2013: 29 · 2012: 22
FWCI
6.77
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
Keywords
paclitaxel, polymeric micelles, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, neutropenia, hypersensitivity, pancreatic cancer, cholangiocarcinoma, gastric cancer, colon cancer, accelerated titration
MeSH terms
Adult, Aged, Antineoplastic Agents, Phytogenic, Digestive System Neoplasms, Female, Humans, Male, Micelles, Middle Aged, Tomography, X-Ray Computed, Paclitaxel, Maximum Tolerated Dose, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. https://app.cochat.ai/papers/10.1038/sj.bjc.6603855
The paper
Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., & Matsumura, Y. (2007). A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6603855

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.